Grieco Paolo, Cai Minying, Han Guoxia, Trivedi Dev, Campiglia Pietro, Novellino Ettore, Hruby Victor J
Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA.
Peptides. 2007 Jun;28(6):1191-6. doi: 10.1016/j.peptides.2007.02.012. Epub 2007 Mar 1.
Recently we have demonstrated that replacing His(6) by constrained amino acids(2) in the well-known antagonist SHU-9119 resulted in potent and selective antagonist ligands especially at the hMC3R and hMC5 receptors. With the aim to further explore position 6 in the sequence of SHU-9119 and MT-II, we have designed, synthesized, and pharmacologically characterized a series of peptide analogues of MT-II and SHU-9119 at the human melanocortin receptors subtypes MC3R, MC4R and MC5R. All these peptides were modified at position 6 with constrained amino acids which are commercially available. In this study, we have identified new selective ligands for the hMC4R, and an antagonist for the hMC3/hMC4 receptors. Additionally, we have discovered an interesting new selective antagonist at the hMC3R, Ac-Nle-c[Asp-betaAla-DNal(2')-Arg-Trp-Lys]-NH(2) (2, PG-106) which represents an important tool in further biological investigations of the hMC3R. PG-106 will be useful in further efforts to differentiate the substructural features responsible for selectivity at the hMC3R, hMC4R, and hMC5R.
最近我们已经证明,在著名的拮抗剂SHU-9119中用受限氨基酸取代His(6)会产生强效且选择性的拮抗剂配体,尤其是在人MC3R和hMC5受体上。为了进一步探索SHU-9119和MT-II序列中的第6位,我们设计、合成并对一系列MT-II和SHU-9119的肽类似物在人黑皮质素受体亚型MC3R、MC4R和MC5R上进行了药理学表征。所有这些肽在第6位都用市售的受限氨基酸进行了修饰。在本研究中,我们鉴定出了新的hMC4R选择性配体以及一种hMC3/hMC4受体拮抗剂。此外,我们还发现了一种有趣的新型hMC3R选择性拮抗剂Ac-Nle-c[Asp-βAla-DNal(2')-Arg-Trp-Lys]-NH(2)(2,PG-106),它是hMC3R进一步生物学研究中的重要工具。PG-106将有助于进一步区分在hMC3R、hMC4R和hMC5R上负责选择性的亚结构特征。